Janssen Presents P-III Induction Study (QUASAR) Results of Tremfya (guselkumab) for Moderately to Severely Active Ulcerative Colitis at DDW 2023
Shots:
- The new efficacy & safety data from the P-III study evaluating Tremfya vs PBO in 1064 patients who had an inadequate response or intolerance to conventional and/or advanced therapies
- The results showed clinical remission (22.6% vs 7.9%) @12wk.; symptomatic remission (22.6% vs 12.9%) @4wk. & 49.9% vs 20.7% @12wk. Tremfya-treated patients @12wk. showed a clinical response (61.5% vs 27.9%); endoscopic improvement (26.8% vs 11.1%); histo-endoscopic mucosal (23.5% vs 7.5%) & endoscopic normalization (15.0% vs 5.0%)
- Frequencies of TEAEs were comparable with fewer SAEs (2.9% vs 7.1%) & AEs leading to discontinuation (1.7% vs 3.9%). The safety results were consistent with a known safety profile of Tremfya in approved indications
Ref: PRnewswire | Image: Janssen
Related News:- Janssen Reports Post-Hoc Analysis of Tremfya (guselkumab) in P-III (DISCOVER-2) Study for Active Psoriatic Arthritis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
